Search - tctmd.com

Displaying 1 - 20 of 172

Sort: Relevancy | Date

News Daily News

FAME 2 at 10 Years: Less Urgent Revascularization With FFR-Guided PCI

Michael O'Riordan

January 26, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

Todd Neale

November 13, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Daily News

Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients

Caitlin E. Cox

October 16, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News SCCT 2025

AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD

Yael L. Maxwell

July 22, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

No Change in HF Outcomes When Private Equity Buys the Hospital

News Daily News

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

Michael O'Riordan

June 16, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

Advertisement

FAME 2 at 10 Years: Less Urgent Revascularization With FFR-Guided PCI

Year in Review: Top Prevention Stories of 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Risk Calculators Miss Many Patients Who Present With First MI

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients

ACC: It’s Time for Clinicians to Address Inflammation in CVD

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

AI-QCT Possibly Lessens Gap Between Ideal vs Actual Care for Patients at Risk of ASCVD

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Private Equity-Backed Hospitals Appear to 'Cherry-Pick' HF Patients

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content